Atea Pharmaceuticals Inc. News, Atea Pharmaceuticals Inc. Quote, AVIR Quote

Atea Pharmaceuticals Inc. (NQ:AVIR) Delayed: 4.87 +0.15 (3.18%)

Prev. Close

$4.72

Today 6M 1Y 5Y

Open

$4.65

52 Wk High

$2.00

52 Wk Low

$1.15

Day High

$4.90

Day Low

$4.64

P/E

N/A

EPS

$0.00

Volume

225,627

Friends, Peers and Foes (?): COYA, ABBV, CARM, LLY, MEIP (more...)

ALERTS | RSS

Jul 14, 2026 07:00 AM Atea Pharmaceuticals starts Phase 1 trial of AT-587 for hepatitis E
Jul 14, 2026 07:00 AM Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus
Jun 25, 2026 07:01 AM Atea Pharmaceuticals completes enrollment in phase 3 HCV trial
Jun 25, 2026 07:00 AM Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
Jun 23, 2026 05:00 PM Form 4 Atea Pharmaceuticals, For: Jun 18 Filed by: Lucidi Bruno
Jun 23, 2026 05:00 PM Form 4 Atea Pharmaceuticals, For: Jun 18 Filed by: BERGER FRANKLIN M
Jun 23, 2026 05:00 PM Form 4 Atea Pharmaceuticals, For: Jun 18 Filed by: Berman Howard
Jun 23, 2026 05:00 PM Form 4 Atea Pharmaceuticals, For: Jun 18 Filed by: KIRSCH ARTHUR S
Jun 23, 2026 05:00 PM Form 4 Atea Pharmaceuticals, For: Jun 18 Filed by: Murphy Polly A.
Jun 23, 2026 05:00 PM Form 4 Atea Pharmaceuticals, For: Jun 18 Filed by: Polsky Bruce

Entities mentioned with AVIR

View All Entities